Stern Investor Relations and LaVoie Group Selected as IR, PR Agencies of
WALTHAM, Mass., March 18 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc., (Amex: ILI), announced today that it has retained two premier life science communications firms, Stern Investor Relations, Inc., and LaVoie Group, as agencies of record to provide investor relations and public relations services, respectively.
The two firms will provide strategic counsel and execution, will lead efforts to communicate Interleukin Genetics' vision to use the science of applied genetics to personalize health management and will support the Company's strategy to establish additional partnerships and relationships with biotechnology and pharmaceutical companies.
Lewis H. Bender, Chief Executive Officer commented, "Interleukin Genetics has a strong message on the value of diagnostic testing to empower consumers to personalize their health. With the addition of these two firms, I am confident that we will deliver our message more effectively to our key constituencies."
About LaVoie Group
LaVoie Group provides strategic, integrated marketing and communications- including marketing strategy, corporate communications, as well as public and investor relations to life sciences and healthcare companies. LaVoie Group's clients range from start-ups to industry leaders. For more information, visit http://www.lavoiegroup.com.
About Stern Investor Relations
Stern Investor Relations provides investor relations consulting
services to biotechnology and healthcare companies. Stern IR develops and
implements strategic investor relations programs design
|SOURCE Interleukin Genetics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved